晶華新材(603683.SH)擬放棄對安徽晶睿同比例增資 持股降至40%
格隆匯8月25日丨晶華新材(603683.SH)公佈,公司控股子公司安徽晶睿光電科技有限公司(以下簡稱“安徽晶睿”)擬增加註冊資本至5040萬元。其中,深圳睿得光電合夥企業(有限合夥)(以下簡稱“深圳睿得”)擬認繳新增註冊資本2,016萬元,定遠晶睿晟科技合夥企業(有限合夥)(以下簡稱“定遠晶睿晟”)擬認繳新增註冊資本224萬元,公司綜合考慮整體利益,決定放棄對安徽晶睿進行同比例增資。
本次增資完成後,深圳睿得和定遠晶睿晟將分別持有安徽晶睿50%與10%的股權;公司持股比例將由72%下降至40%,安徽晶睿不再納入公司財務報表合併範圍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.